SCHEMBL3982004

SCHEMBL3982004

Nc1ncnc2snc(-c3ccc4ccc(-c5ccccc5)nc4n3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.52
LIMK1 P53667 2/20 0.44
FLT1 P17948 3/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43
LCK P06239 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
MET P08581 1/20 0.43
PDGFRB P09619 1/20 0.43
FGFR1 P11362 1/20 0.43
PDGFRA P16234 1/20 0.43
PRKACA P17612 1/20 0.43
LTK P29376 1/20 0.43
MAP2K2 P36507 1/20 0.43
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977004 0.83 PPARG (0.47) KDRLIMK1FLT1DAPK3PRKD3
SCHEMBL3985507 0.82 KDR (0.55) KDRLIMK1FLT1DAPK3PRKD3
SCHEMBL3980741 0.80 KDR (0.47) KDRLIMK1FLT1DAPK3PRKD3
SCHEMBL3977031 0.78 KDR (0.67) KDRLIMK1FLT1DAPK3PRKD3
SCHEMBL3980027 0.71 KDR (0.50) KDRLIMK1FLT1DAPK3PRKD3
SCHEMBL4478592 0.70 KDR (0.68) KDRFLT1LCKRETMAP2K2
SCHEMBL3985483 0.70 KDR (0.52) KDRFLT1MAP4K4ABL1LCK
SCHEMBL4469181 0.69 KDR (1.00) KDRLIMK1FLT1DAPK3PRKD3
SCHEMBL12915446 0.69 MEN1 (0.59) PRKACAALKCYP1A2CYP2C9HPGD
SCHEMBL3980068 0.69 KDR (0.42) KDRLIMK1FLT1DAPK3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US claimed
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors IGF1R, BRCA1, MAP2K6 KDR 2130/4885LIMK1 913/4885FLT1 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.